IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Wojciechowski, Jonathan
Stevens, Molly M.
Foote, James E. J.
Abrégé
The invention relates to a compound of formula I, wherein: A, B, R1, R2, L1, m and n are as defined in the specification, or a salt or solvate thereof, which compounds are useful for forming Raman-tagged bioconjugates with a biomarker and/or biomolecule and are detectable with Raman spectroscopy
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Stafford, Jason
Matar, Omar
Petit, Camille
Abrégé
The invention provides an apparatus for fluidic exfoliation of a layered material comprising: a housing of circular cross-section defined by a housing wall; a hollow rotor of circular cross-section having a first end and a second end and a wall positioned therebetween arranged concentrically within the housing, wherein the wall of the hollow rotor defines an inner chamber and the space in between the wall of the hollow rotor and the housing wall defines an outer chamber, and wherein a fluid flow path is provided between the inner chamber and the outer chamber; a fluid inlet in fluid communication with the inner chamber or the outer chamber; and a fluid outlet in fluid communication with the other of the inner chamber or the outer chamber; wherein the outer chamber has a width such that on passage of a fluid comprising the layered material from the inlet to the outlet through the outer chamber, a shear rate sufficient to exfoliate the layered material may be applied to the fluid comprising the layered material in the outer chamber by rotation of the hollow rotor.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Stevens, Molly Morag
Aviles, Marta Broto
Adrianus, Christopher
Dissanayake-Perera, Schan
Abrégé
The present disclosure relates to systems and methods of detecting nucleic acids using a combination of a Cas-based reaction with catalytic nanoparticles. Provided is a nucleic acid detection system for detecting one or more target nucleic acids, the system comprising a CRISPR effector protein; one or more guide RNAs (gRNA), each of which is specific for the one or more target nucleic acids; and a reporter RNA molecule; and a catalytic nanoparticle. Also provided is a reporter RNA molecule for a CRISPR detection assay. The disclosure also relates to uses, methods and kits for detecting one or more target nucleic acids. The uses, methods and kits extend to diagnosing a disease in a patient based on the presence of a nucleic acid of interest.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12Q 1/6816 - Tests d’hybridation caractérisés par les moyens de détection
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Riglar, David
Brown, André
Short, Nina
Abrégé
The present invention relates to peptides, and particularly, although not exclusively, to peptides isolated from the human gut microbiome which impact the gut-brain-axis in a subject. The invention extends to the use of these peptides in therapy, as well as novel compositions, therapies, and methods for treating, preventing, or ameliorating diseases caused by, or associated with, the gut-brain-axis.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Song, Qilei
Wang, Anqi
Yang, Dingchang
Meng, Naiqi
Wong, Tobias Pei Wei Yong
Iguodala, Sunshine
Abrégé
The present application relates to a polymer (such as a polymer of intrinsic microporosity). This comprises a polymeric backbone comprising contorted aromatic moieties and at least one side group as defined herein.
C08G 10/00 - Polymères de condensation obtenus uniquement à partir d'aldéhydes ou de cétones avec des hydrocarbures aromatiques ou avec leurs dérivés halogénés
C08G 10/02 - Polymères de condensation obtenus uniquement à partir d'aldéhydes ou de cétones avec des hydrocarbures aromatiques ou avec leurs dérivés halogénés d'aldéhydes
C08G 65/40 - Composés macromoléculaires obtenus par des réactions créant une liaison éther dans la chaîne principale de la macromolécule à partir de composés hydroxylés ou de leurs dérivés métalliques dérivés des phénols à partir des phénols et d'autres composés
C08G 65/48 - Polymères modifiés par post-traitement chimique
B01D 71/00 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leurs matériauxProcédés spécialement adaptés à leur fabrication
C08G 61/00 - Composés macromoléculaires obtenus par des réactions créant une liaison carbone-carbone dans la chaîne principale de la macromolécule
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Rodriguez Manzano, Jesus
Stringer, Oliver
Cavuto, Matthew
Malpartida-Cardenas, Kenny
Abrégé
The present disclosure provides a lyophilized composition for use in a colorimetric nucleic acid amplification reaction. Also provided are processes for producing a lyophilized composition and methods for determining the presence of a target nucleic acid in a test sample or diagnosing or treating infection by a pathogen in a subject.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Shattock, Robin
Nogareda, Laia
Abrégé
The present invention relates to RNA molecules, and particularly, although not exclusively, to unlocked nucleotides (UNAs) and unlocked nucleic acid (UNA)-RNA molecules per se, to methods for preparing UNA-RNA molecules, and to methods for translating UNA-RNA molecules into protein. The invention extends to improved methods for forming UNA-RNA by in vitro transcription, and to the resultant UNA-RNA molecules. Furthermore, the invention relates to novel methods for enhancing the expression and/or translation of RNA, i.e. protein expression, and to methods for improving the stability of an RNA molecule. The invention also involves reducing the activation of innate sensing, interferon generation and/or degradation of an RNA molecule in a host. The invention also incorporates the use of the UNA-RNA molecules in vaccines and other therapeutic pharmaceutical compositions, and their use in immunisation and therapy, such as RNAi, gene therapy, gene editing and protein replacement. Furthermore, the invention relates to novel methods for enhancing translation of RNA, i.e. protein expression.
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Kapelyukh, Ivan
Johns, Edward
Abrégé
A method of determining an arrangement for objects comprises obtaining first data representing a first arrangement of first objects in a scene; inputting the obtained first data into a trained machine learning model to determine a first cost value for the first arrangement. The first cost value is indicative of an extent to which the first arrangement differs from an optimum arrangement of the first objects according to a cost function that the machine learning model has been trained to provide. The method comprises determining a second arrangement for the first objects based on the first cost value.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06T 1/00 - Traitement de données d'image, d'application générale
G06V 20/70 - Étiquetage du contenu de scène, p. ex. en tirant des représentations syntaxiques ou sémantiques
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A01K 67/0275 - Vertébrés modifiés génétiquement, p. ex. transgéniques
C07K 14/465 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant d'oiseaux
The present invention relates to the metal enhanced fluorescence and chips designed to improve the usefulness of current chips. Specifically, the chips of the present invention are able to enhance fluorescence from a range of spectral regions.
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Davison, Andrew
Haughton, Iain
Johns, Edward
Mouton, Andre
Sucar, Edgar
Abrégé
A computer implemented method for updating a scene representation model is disclosed. The method comprises obtaining a scene representation model representing a scene having one or more objects, the scene representation model being configured to predict a value of a physical property of one or more of the objects; obtaining a value of the physical property of at least one of the objects, the obtained value being derived from a physical contact of a robot with the at least one object; and updating the scene representation model based on the obtained value. An apparatus is also disclosed.
G05D 1/246 - Dispositions pour déterminer la position ou l’orientation utilisant des cartes d’environnement, p. ex. localisation et cartographie simultanées [SLAM]
G05D 105/80 - Applications spécifiques des véhicules commandés pour la collecte d’informations, p. ex. recherche universitaire
G06T 7/50 - Récupération de la profondeur ou de la forme
G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras
G06V 20/70 - Étiquetage du contenu de scène, p. ex. en tirant des représentations syntaxiques ou sémantiques
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
ACADEMISCH MEDISCH CENTRUM (Pays‑Bas)
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (Pays‑Bas)
Inventeur(s)
Jackson, Heather
Kaforou, Myrsini
Levin, Michael
Zandstra, Judith
Kuijpers, Taco
Isaak De Jonge, Marinus
Abrégé
The invention relates to protein signatures, and particularly, although not exclusively, to protein signatures detected in methods and kits for distinguishing between and diagnosing a bacterial and/or viral infection. The invention also relates to the use of a protein signature as a diagnostic or prognostic biomarker for a bacterial and/or viral infection.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
Imperial College Innovations Limited (Royaume‑Uni)
VaxEquity Ltd (Royaume‑Uni)
Inventeur(s)
Mckay, Paul
Shattock, Robin
Abrégé
The invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Choi, James
Jiang, Zheng
Abrégé
The present disclosure relates to a device for detecting mechanical force at multiple regions of a surface, the device comprising: a plurality of sensor bodies, wherein each of the plurality of sensor bodies comprises: a deformable material; and a piezoelectric sensor configured to detect a displacement of a region of the surface upon deformation of the deformable material by the region of the surface; wherein the piezoelectric sensor of a first one of the plurality of sensor bodies is isolated from the piezoelectric sensor of a second one of the plurality of sensor bodies such that deformation of the piezoelectric sensor of the first one of the plurality of sensor bodies does not cause deformation of the piezoelectric sensor of the second one of the plurality of sensor bodies.
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
G01L 1/16 - Mesure des forces ou des contraintes, en général en utilisant les propriétés des dispositifs piézo-électriques
H10N 30/30 - Dispositifs piézo-électriques ou électrostrictifs à entrée mécanique et sortie électrique, p. ex. fonctionnant comme générateurs ou comme capteurs
A wireless power transfer system comprising: a transmitter unit, the transmitter unit comprising a first transceiver coupled to a first inductive coil and configured to drive the first inductive coil; and a receiver unit, the receiver unit comprising a second transceiver coupled to a second inductive coil for inductive coupling with the first inductive coil; wherein the receiver unit further comprises an injection-locked oscillator coupled to the second transceiver for defining an oscillation frequency of the second transceiver, the injection-locked oscillator configured to synchronize with a driving frequency of the transmitter unit.
H02J 50/12 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant un couplage inductif du type couplage à résonance
H02J 50/80 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique mettant en œuvre l’échange de données, concernant l’alimentation ou la distribution d’énergie électrique, entre les dispositifs de transmission et les dispositifs de réception
H02J 50/00 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique
16.
ZINC FINGER PEPTIDES, ENCODED NUCLEIC ACIDS, METHODS AND USES
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
White, Gavin
Hales, Alistair
Patel, Yatish
Offer, Gregory
Abrégé
There is provided apparatuses and methods for measuring at least one thermal property of a body. The methods involve causing a symmetrical thermal boundary condition across the body such that measurements taken are not affected by the structure of the body being measured.
G01N 25/20 - Recherche ou analyse des matériaux par l'utilisation de moyens thermiques en recherchant la production de quantités de chaleur, c.-à-d. la calorimétrie, p. ex. en mesurant la chaleur spécifique, en mesurant la conductivité thermique
18.
APPARATUS AND METHOD FOR INTRAOPERATIVE REAL-TIME TUMOUR TISSUE DISCRIMINATION
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Wong, Steven
Ekanayake, Jinendra
Constandinou, Timothy
Abrégé
Apparatus for discriminating between tumour tissue and non-tumorous tissue, the apparatus comprising: a handheld bioimpedance probe having a plurality of electrodes mounted thereon, wherein the plurality of electrodes are greater than four in number; a current source configured to generate a stimulation current; a voltage sensor; one or more multiplexers coupled between the current source, the voltage sensor and the electrodes and configured to changeably select a subset of four electrodes from the plurality of electrodes, and, for each selected subset of four electrodes, to switch between a plurality of switching configurations, wherein, in each switching configuration, a first pair of the selected subset of four electrodes are connected to the current source, and a second pair of the selected subset of four electrodes are connected to the voltage sensor, the electrodes that constitute the first pair and the electrodes that constitute the second pair changing from one switching configuration to the next; and processor-controlled circuitry configured to: control the selection of the subset of four electrodes by the one or more multiplexers; control the switching configuration of the one or more multiplexers with respect to the selected subset of four electrodes; control the generation of the stimulation current by the current source and the application of the stimulation current to the first pair of electrodes of each switching configuration, such that, in use, the stimulation current flows through tissue between the first pair of electrodes; control the measurement, by the voltage sensor, of the voltage between the second pair of electrodes of each switching configuration, across the tissue; determine, based on the applied current and the measured voltages for each switching configuration, a measure of relative impedance of the tissue for each switching configuration; and supply such impedance measurements as output data to a data analyser to enable real-time discrimination of the tissue to be performed, based on the impedance measurements.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
O'Brien, Ciaran David
Hellgardt, Klaus
Holtze, Christian
Guriyanova, Svetlana
Metzger, Lukas Karl
Voges, Matthias
Abrégé
The present invention relates to a process for the separation of enantiomeric crystals by enantioselective crystal floatation and to a process in which preferential crystallization is combined with enantioselective crystal floatation.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Macintyre, David A.
Pruski, Pamela
Dos Santos Correia, Gonçalo
Lewis, Holly
Bennett, Phillip R.
Takats, Zoltan
Abrégé
The present invention relates to methods for obtaining a metabolic signature in a subject, said method being applicable for a range of purposes, including diagnosing disease, monitoring disease progression and/or determining a suitable treatment plan.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Wong, Wei Jie Garrett
Lim, Li Rong
Go, Maybelle Darlene Kho
Yew, Wen Shan
Freemont, Paul S.
Bell, David John
Abrégé
Modified cells suitable for the production of ergot alkaloids include engineered recombinant cells having one or more genes that code for one or more enzymes in the biosynthetic pathway from tryptophan to D-lysergic acid (DLA). Methods of culturing the engineered recombinant cells can be used for the production of DLA and other ergot alkaloids.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
C12N 9/08 - Oxydoréductases (1.), p. ex. luciférase agissant sur le peroxyde d'hydrogène comme accepteur (1.11)
C12P 17/18 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles condensés entre eux ou condensés avec un système carbocyclique commun, p. ex. rifamycine
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Stenning, Kilian James Darrie
Xiao, Xiaofei
Holder, Holly
Carter Gartside, Jack
Oulton, Rupert Francis Maximillian
Branford, William Richard
Abrégé
A magnetic medium is described which includes a thin film magnet structure formed of a ferromagnetic alloy or compound. The thin film magnet structure includes one or more ferromagnetic domains and is coupled to one or more optical structures. Each of the one or more ferromagnetic domains have a magnetization that is switchable between two or more states. Each of the one or more optical structures is configured to increase absorbance of light at a target wavelength in the thin film magnet structure, such that in response to illumination of a ferromagnetic domain with continuous-wave light including the target wavelength, that ferromagnetic domain undergoes all-optical magnetic switching.
G11B 11/105 - Enregistrement sur, ou reproduction depuis le même support d'enregistrement, dans lesquels, pour ces deux opérations, les procédés ou les moyens sont couverts par différents groupes principaux des groupes ou par différents sous-groupes du groupe Supports d'enregistrement correspondants utilisant l'enregistrement par magnétisation ou démagnétisation utilisant un faisceau de lumière ou un champ magnétique pour l'enregistrement et un faisceau de lumière pour la reproduction, p. ex. enregistrement thermomagnétique induit par la lumière ou reproduction par l'effet Kerr
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Huang, Chun
Abrégé
The present application relates to an electrode comprising a redox-active material and a low- dimensional carbon material. At least around 70% of the surface of the electrode comprises at least one layer comprising the low-dimensional carbon material. The electrode comprises at most around 45 wt% low-dimensional carbon material, based on the total weights of low-dimensional carbon material and redox-active material in the electrode.
H01M 4/1391 - Procédés de fabrication d'électrodes à base d'oxydes ou d'hydroxydes mixtes, ou de mélanges d'oxydes ou d'hydroxydes, p. ex. LiCoOx
H01M 4/1395 - Procédés de fabrication d’électrodes à base de métaux, de Si ou d'alliages
H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
H01M 4/48 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques
H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p. ex. LiMn2O4 ou LiMn2OxFy
H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p. ex. LiNiO2, LiCoO2 ou LiCoOxFy
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p. ex. liants, charges
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Klug, David
Abrégé
A method of determining the geometry of interaction between a protein or nucleic acid and one or more chemical entities, the method comprising the steps of: (a) providing an experimentally obtained multi-dimensional spectrum for a sample comprising the protein or nucleic acid and the one or more chemical entities; (b) providing two or more structural hypotheses; (c) obtaining a computationally generated multi-dimensional spectrum of the same type as the experimentally obtained multi-dimensional spectrum for each of the two or more structural hypotheses; (d) determining which of the computationally generated multi-dimensional spectra best fits the experimentally obtained multi-dimensional spectrum; and (e) based on step (d), identifying the geometry of interaction between the protein or nucleic acid and one or more chemical entities.
G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire
G01N 21/35 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge
G16B 40/10 - Traitement du signal, p. ex. de spectrométrie de masse ou de réaction en chaîne par polymérase
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Brown, Andre
Abrégé
A method of determining an effect of a modified peptide is disclosed. The method comprises comparing a behavioural phenotype of an organism, the organism having ingested a cell culture, wherein cells in the cell culture are configured to produce a modified peptide, with a reference behavioural phenotype of organisms of the same species, and determining whether the peptide has an effect based on the difference between the behavioural phenotype and the reference behavioural phenotype.
G06V 10/771 - Sélection de caractéristiques, p. ex. sélection des caractéristiques représentatives à partir d’un espace multidimensionnel de caractéristiques
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Shattock, Robin
Nogareda, Laia
Abrégé
The present invention relates to RNA molecules, and particularly, although not exclusively, to methods for preparing RNA molecules, and to methods for translating RNA molecules into protein. The invention extends to improved methods for forming RNA by in vitro transcription, and to the resultant RNA molecules. Furthermore, the invention relates to novel methods for enhancing the expression and/or translation of RNA, i.e. protein expression, and to methods for improving the stability of an RNA molecule. The invention also involves reducing the activation of innate sensing, interferon generation and/or degradation of an RNA molecule in a host. The invention also incorporates the use of the RNA molecules in vaccines and other therapeutic pharmaceutical compositions, and their use in immunisation and therapy, such as RNAi, gene therapy, gene editing and protein replacement. In particular, the invention relates to locked nucleotides and locked nucleic acid (LNA)-RNA molecules, and the use or incorporation of such locked nucleotides and LNA-RNA molecules in any of the above applications.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Hall, Thomas Ainsley Grant
Arkel, Richard Jan Van
Cegla, Frederic
Abrégé
An aspect of the disclosure provides a bone implant system for stimulating growth in bone tissue cells of a human or animal patient, the system comprising: a bone implant (530); and an apparatus configured to be carried by the bone implant, the apparatus comprising: an energy provider (512), comprising an electromagnetic coupler configured to obtain electromagnetic energy via an electromagnetic field from an energy source disposed outside a body of the patient, wherein the electromagnetic coupler is carried by an external surface of the bone implant system; and a stimulator (517) configured to provide, based on energy from the energy provider, at least one of electrical or mechanical stimulus to a bone into which the bone implant is implanted.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Al Musaimi, Othman
Williams, Daryl Robert
Abrégé
The present invention relates to methods for the synthesis of peptides and related compounds supported on a solid polymeric resin. The inventive method provides synthetic schemes that permit the coupling of two or more peptide fragments attached to the same polymeric support, in a fashion that allows access to previously unobtainable structures, and provides a more convenient and higher-yielding approach to known peptides, including those of commercial significance.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Runciman, Mark
Avery, James
Mylonas, George
Abrégé
An aspect of the disclosure provides a surgical robot (10) for deployment in an internal body lumen of a human or animal subject, the robot comprising: an inflatable scaffold (12) having a collapsed state for delivery to a target site in the lumen and an inflated state in which the scaffold defines an open cavity (18), a manipulator (14) movable in the cavity for manipulating a medical device; and a soft actuator (16) operable by fluid pressure to move the manipulator (14) by applying force between the scaffold (12) and the manipulator, wherein the scaffold (12) is arranged around the soft actuator (16) to provide protection between the soft actuator and the body lumen.
A61B 34/00 - Chirurgie assistée par ordinateurManipulateurs ou robots spécialement adaptés à l’utilisation en chirurgie
A61M 25/01 - Introduction, guidage, avance, mise en place ou maintien en position des cathéters
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
The present invention relates to bioproduction of dyes and dyed biomaterials, and in particular relates to cells and methods for producing indigoidine. The invention also provides a dyed cellulose material and methods for producing the same.
C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
C12P 17/16 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Kyriacou, Christopher
Kim, Sung Hye
Macintyre, David
Bennett, Phillip
Bourne, Tom
Terzidou, Vasso
Abrégé
The present invention provides a method for predicting an outcome of pregnancy, particular for predicting the likelihood of ectopic pregnancy (EP) or viable intrauterine pregnancy (VIUP), and methods for determining appropriate protocols for subjects with a pregnancy of unknown location (PUL) based on such an outcome, comprising determining the expression level of one or more specific miRNA molecules that are differentially expressed in scenarios of EP or VIUP, extracted from a biological sample obtained from said subject and comparing to a control value. The present invention also provides biochips and kits for use in carrying out the methods of the invention.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
Board of Regents, The University of Texas System (USA)
Imperial College Innovations Limited (Royaume‑Uni)
Massachusetts Institute of Technology (USA)
Inventeur(s)
Hodes, Marc
Bahadur, Vaibhav
Crowdy, Darren G.
Papageorgiou, Demetrios T.
Hatton, Trevor Alan
Abrégé
A carbon-capture device and related processes are disclosed. The devices include substrate surfaces having a textured surfaces and a liquid sorbent contacting the texture surface in either a Cassie-Baxter state, in the case of a texture omniphobic surface or a plurality of re-entrant features or a Wenzel state, in the case of a textured omniphilic surface. The liquid sorbent reversibly captures a chemical species, which can usefully be carbon dioxide. This reversible capture can be exploited to capture and sequester carbon or other chemical species of interest.
B32B 15/08 - Produits stratifiés composés essentiellement de métal comprenant un métal comme seul composant ou comme composant principal d'une couche adjacente à une autre couche d'une substance spécifique de résine synthétique
B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
B32B 3/26 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche continue dont le périmètre de la section droite a une allure particulièreProduits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche comportant des cavités ou des vides internes
B32B 27/20 - Produits stratifiés composés essentiellement de résine synthétique caractérisée par l'emploi d'additifs particuliers utilisant des charges, des pigments, des agents thixotropiques
B32B 27/32 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyoléfines
The present invention provides compositions and methods for enhancing fluorescence from emitters that emit in the NIR-II and NIR-III. The compositions have particular use in both in vitro diagnostics, and in the live imaging of tissue during surgery, for example during removal of a tumour.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Chan, Bee Eng Mary
Pethe, Kevin
Gründling, Angelika
Koh, Chong Hui
Lambu, Mallikharjuna Rao
Kok, Zhi Yuan
Wei, Guangmin
Tatina, Madhu Babu
Abrégé
Disclosed herein is a compound according to formula Ia: Also disclosed herein are a pharmaceutical composition comprising the compound as aforementioned, use of the compound as aforementioned, a method of treating one or both of a microbial and a fungal infection comprising the step of administering a pharmaceutically effective amount of the compound as aforementioned or the pharmaceutical composition as aforementioned, and an antimicrobial and/or antifungal detergent composition comprising the compound as aforementioned, and a surfactant.
C08G 73/06 - Polycondensats possédant des hétérocycles contenant de l'azote dans la chaîne principale de la macromoléculePolyhydrazidesPolyamide-acides ou précurseurs similaires de polyimides
C08L 79/04 - Polycondensats possédant des hétérocycles contenant de l'azote dans la chaîne principalePolyhydrazidesPolyamide-acides ou précurseurs similaires de polyimides
A61K 31/787 - Polymères contenant de l'azote contenant des hétérocycles ayant l'azote comme hétéro-atome d'un cycle
A61K 8/40 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant de l'azote
METHOD FOR AUTOMATICALLY MAINTAINING AND IMPROVING A HYDRAULIC MODEL FOR A WATER DISTRIBUTION NETWORK, AND CONTROLLING THE OPERATION OF A WATER DISTRIBUTION NETWORK USING THE MAINTAINED HYDRAULIC MODEL
A computer-implemented method of controlling operation of a water distribution network, WDN, comprising obtaining data pertaining to parameters of the WDN; comparing the data with a hydraulic model of the WDN; determining an error value based on the comparing the data with the hydraulic model; determining that the error value is below a threshold; using the data to obtain an updated hydraulic model; and using the updated hydraulic model to control one or more elements of the WDN.
The disclosure related to an interferometer comprising a first mirror array comprising a first mirror and a second mirror; and an adjustable beam-steering device. The beam steering device configured to receive a first beam and a second beam, split from a source beam; steer the first beam onto the first mirror of the first mirror array; and steer the second beam onto the second mirror of the first mirror array. The first mirror array is configured to reflect, by the first mirror, the first beam, and reflect, by the second mirror, the second beam, to combine the first beam and the second beam to generate an interference pattern.
G01B 9/02001 - Interféromètres caractérisés par la commande ou la génération des propriétés intrinsèques du rayonnement
G01B 9/02015 - Interféromètres caractérisés par la configuration du parcours du faisceau
G01B 11/25 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour mesurer des contours ou des courbes en projetant un motif, p. ex. des franges de moiré, sur l'objet
G02B 26/08 - Dispositifs ou dispositions optiques pour la commande de la lumière utilisant des éléments optiques mobiles ou déformables pour commander la direction de la lumière
37.
DECODING SURFACE FINGERPRINTS FOR PROTEIN-LIGAND INTERACTIONS
ÉCOLE POLYTECHNIQUE FÊDÉRALE DE LAUSANNE (EPFL) (Suisse)
IMPERIAL COLLEGE INOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Ferreira De Sousa Correia, Bruno Emanuel
Bronstein, Michael
Igashov, Llia
Abrégé
Small molecules have been the preferred modality for drug development and therapeutic interventions. This molecular format presents a number of advantages, e.g. long half-lives and cell permeability, making it possible to access a wide range of therapeutic targets. However, finding small molecules that engage “hard-to-drug” protein targets specifically and potently remains an arduous process, requiring experimental screening of extensive compound libraries to identify candidate leads. The search continues with further optimization of compound leads to meet the required potency and toxicity thresholds for clinical applications. Here, we propose a new computational workflow for high-throughput fragment-based screening and binding affinity prediction where we leverage the available protein-ligand complex structures using a state-of-the-art protein surface embedding framework (dMaSIF). We developed a tool capable of finding suitable ligands and fragments for a given protein pocket solely based on protein surface descriptors, that capture chemical and geometric features of the target pocket. The identified fragments can be further combined into novel ligands. Using the structural data, our ligand discovery pipeline learns the signatures of interactions between surface patches and small pharmacophores. On a query target pocket, the algorithm matches known target pockets and returns either potential ligands or identifies multiple ligand fragments in the binding site. Our binding affinity predictor is capable of predicting the affinity of a given protein-ligand pair, requiring only limited information about the ligand pose. This enables screening without the costly step of first docking candidate molecules. Our framework will facilitate the design of ligands based on the target's surface information. It may significantly reduce the experimental screening load and ultimately reveal novel chemical compounds for targeting challenging proteins.
C08J 11/16 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p. ex. dévulcanisation par traitement avec une substance inorganique
B29B 17/04 - Désintégration des matières plastiques
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Li, Weishu
Lv, Jiaxin
Yu, Junquan
Shi, Zhusheng
Lin, Jianguo
Abrégé
An apparatus for extruding a material, the apparatus comprising: a block which includes two or more extrusion containers composed of heat resisting material, the containers being arranged to receive billets of the extruding material; a die set arranged downstream of the block including the two or more extrusion containers; and one or more rams, wherein the one or more rams are aligned with the axes of the extrusion containers and are arranged to push the billets of material through the extrusion containers into the die set; wherein the die set includes an upper die including two or more extrusion channels for extruding material from each of the extrusion containers, and a lower die incorporating a welding chamber, wherein two or more extruded billets from each of the extrusion channels are welded together and passed out through the exit of the die set.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Kemp, Paul
Abrégé
The present invention relates to isolated oligonucleotides for treating or preventing inflammation or muscle atrophy. In particular, the invention relates to isolated antisense oligonucleotides which bind to a lncRNA, wherein the lncRNA acts as a molecular sponge for a given miRNA, and wherein the binding of the oligonucleotide to the lncRNA increases the abundance and/or availability of said miRNA in a cell.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Pucci, Nunzio
Arteaga, Juan
Mitcheson, Paul
Abrégé
Disclosed herein are methods and systems of determining a magnetically induced voltage on a coil of a wireless power transmission device. The method comprises supplying DC input power to the wireless power transmission device. It further comprises monitoring a first variable associated with the wireless power transmission device, and monitoring a second variable associated with the wireless power transmission device, wherein at least one of the first and the second variable is derived from a switching waveform. It further comprises determining, based on at least one of the first variable, the second variable, and the relationship between the first variable and the second variable, the magnetically induced voltage on the coil of the wireless power transmission device.
H02J 50/60 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique sensibles à la présence d’objets étrangers, p. ex. détection d'êtres vivants
H02J 50/12 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant un couplage inductif du type couplage à résonance
The disclosure relates to a valve (20) for use with breathing assistance apparatus. The valve comprises: a valve body (25) defining first, second and third ports (21, 22, 23); a valve core (27) defining a ported chamber (40) rotatable about a valve axis (28) between: a first stable configuration in which the ported chamber provides fluid communication between the first port and the second port and isolates the third port from the first and second ports; and a second stable configuration in which the ported chamber provides fluid communication between the first port and the third port and isolates the second port from the first and third ports, wherein an outer surface (34) of the valve core is configured to engage with an inner surface (32) of the valve body to define a detent for resisting rotation of the valve core between the first stable configuration and the second stable configuration; and an actuator (30) configured to overcome the detent to rotate the valve core between the first and second stable configurations.
A61M 16/20 - Valves spécialement adaptées aux dispositifs respiratoires médicaux
F16K 11/083 - Soupapes ou clapets à voies multiples, p. ex. clapets mélangeursRaccords de tuyauteries comportant de tels clapets ou soupapesAménagement d'obturateurs et de voies d'écoulement spécialement conçu pour mélanger les fluides dont toutes les faces d'obturation se déplacent comme un tout comportant uniquement des robinets à boisseau à noix conique
F16K 11/085 - Soupapes ou clapets à voies multiples, p. ex. clapets mélangeursRaccords de tuyauteries comportant de tels clapets ou soupapesAménagement d'obturateurs et de voies d'écoulement spécialement conçu pour mélanger les fluides dont toutes les faces d'obturation se déplacent comme un tout comportant uniquement des robinets à boisseau à noix cylindrique
F16K 31/524 - Moyens mécaniques d'actionnement à manivelle, excentrique ou came à came
F16K 31/56 - Moyens mécaniques d'actionnement sans position intermédiaire stable, p. ex. par à-coup
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Malik, Muhammad
Papavassiliou, Christos
Abrégé
An apparatus for generating random numbers, the apparatus comprising one or more bit stream generators, wherein each bit stream generator comprises: a memristor; a pulse generator configured to: generate a plurality of pulses; and apply the plurality of pulses through the memristor to generate an output comprising a plurality of output pulses; and a comparison means configured to: compare a first sample of the pulsed output with a second sample of the pulsed output; and output, based on the first comparison, information indicative of a randomly generated bit of a random bit stream.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Cegla, Frederic Bert
Challinor, Connor Joe
Abrégé
Systems and methods for ultrasound devices are presented. A system may comprise an ultrasound transducer having a terminal, a driver in electrical communication with the ultrasound transducer via the terminal, and a receiver in electrical communication with the ultrasound transducer via the terminal. The ultrasound transducer is configured to simultaneously transmit and receive a modulated signal and methods allowing for the simultaneous transmission and reception are used.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Griesenbach, Uta
Alton, Eric
Clarke, Nora Katherine
Abrégé
The present invention relates to methods for the production of immune cells and immunomodulatory cells expressing a transgene of interest, using lentiviral vectors. The invention also relates to populations of cells produced by such methods and uses thereof.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The Chancellor, Masters and Scholars of the University of Oxford (Royaume‑Uni)
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Lu, Xin
Xu, Xiao-Ning
Khan, Nadia
Zentelis, Stefanie
Abrégé
This disclosure describes a novel “kick and kill” strategy as an effective cancer therapy for treating virus-associated cancers. In particular, this disclosure provides a method of reactivating a latent Epstein-Barr virus (EBV) in a cell infected with the EBV. Also provided are a method of eliciting or enhancing an immune response against an EBV-positive cancer cell in a subject infected with the EBV and a method of treating a subject having cancer associated with EBV infection.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
A61K 31/4406 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 3, p. ex. zimeldine
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/473 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. acridines, phénantridines
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Chen, Rongjun
Liu, Xuhan
Shattock, Robin
Blakney, Anna
Liu, Yifan
Abrégé
The invention relates to a sub-micron particle comprising a payload molecule and a lipid structure being surrounded by an outer layer comprising an amphiphilic copolymer. The invention extends to method of producing the sub-micron particle. The invention also encompasses pharmaceutical compositions and vaccines comprising the sub-micron particle and medical uses thereof.
The present invention relates to biomaterials, in particular bacterial cellulose and provides means to prepare pigmented cellulose at acidic pH 5.8, wherein cellulose pellicles comprising tyrosinase (EC 1.14.18.1) are melanated using a development solution at pH 6 to 8.5 and comprises tyrosine, cysteine and/or cystine. Further, the invention relates to means of preparing spatially restricted pigmented cellulose using an optogenetic expression system wherein two polymerase or transcription factor domains are split and each linked to a light-inducible dimerization domain. The invention provides corresponding methods and components.
C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
C12P 17/10 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'azote comme unique hétéro-atome du cycle
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Levin, Michael
Cunnington, Aubrey
Kaforou, Myrsini
Herberg, Jethro
Habgood-Coote, Dominic
Abrégé
The invention relates to gene signatures. In particular, the invention relates methods and kits for diagnosing a subject having a disease, by simultaneously discriminating between multiple infectious and inflammatory diseases using a gene signature. The invention also relates to the use of a gene signature as a diagnostic or prognostic biomarker for diseases.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Hanna, George
Woodfield, Georgia
Belluomo, Ilaria
Abrégé
The invention relates to biomarkers, and to novel biological markers for diagnosing colorectal cancer. In particular, the invention relates to the use of these biomarkers as diagnostic and prognostic markers in assays for detecting colorectal cancer, and corresponding methods of detection. The invention also relates to methods of determining the efficacy of treating colorectal cancer with a therapeutic agent, and apparatus for carrying out the assays and methods. The assays are qualitative and/or quantitative, and are adaptable to large-scale screening and clinical trials.
Imperial College Innovations Limited (Royaume‑Uni)
Ecole Polytechnique Federale de Lausanne (Suisse)
Inventeur(s)
Yang, Guang-Zhong
Abdelaziz, Mohamed Ek
Temelkuran, Burak
Leber, Andreas
Sorin, Fabien
Abrégé
A method of manufacturing a fibre comprising a lined channel, using a draw apparatus, the method comprising: providing a preform, comprising a channel extending through the preform, to the draw apparatus; feeding a liner into the channel; heating a portion of the preform; and drawing the heated portion of the preform in order to form a fibre, wherein the liner is held within the channel of the fibre to provide a lined channel within the fibre.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Gill, Deborah
Hyde, Steve
Munis, Altar
Miah, Kamran
Ruffle, Aimee
Munday, Rosie
Viegas, Mariana
Abrégé
The present invention relates to nucleic acid cassettes for gene therapy, particularly to promoter and promoter/enhancer combinations for improved expression of transgenes in a lung parenchyma‐specific/preferred manner. The invention further relates nucleic acid cassettes comprising said promoters and promoter/enhancer combinations, viral and non‐viral vectors comprising such nucleic acid cassettes, and the use of such nucleic acid cassettes and vectors to increase expression of therapeutic proteins by lung parenchyma cells.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
54.
ANTI-CRISPR CONSTRUCT AND ITS USE TO COUNTERACT A CRISPR-BASED GENE-DRIVE IN AN ARTHROPOD POPULATION
Imperial College Innovations Limited (Royaume‑Uni)
Polo D’Innovazione di Genomica Genetica e Biologia SRL (Italie)
Inventeur(s)
Taxiarchi, Chrysanthi
Galizi, Roberto
Crisanti, Andrea
Simoni, Alekos
D'Amato, Rocco
Abrégé
The present invention relates to an anti-CRISPR construct useful to counteract the spread of a gene-drive in an arthropod population. The invention is also concerned with a system comprising the anti-CRISPR construct and a crispr-based gene-drive construct, a method of producing a genetically modified arthropod, a genetically modified arthropod, and a method for counteracting a CRISPR-based gene-drive in an arthropod population.
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Yang, Guang-Zhong
Abdelaziz, Mohamed Ek
Temelkuran, Burak
Lee, Hyun-Taek
Zhao, Jinshi
Seichepine, Florent
Abrégé
A device comprising a bendable fibre comprising a fibre axis, a thermally expandable material and a resistance wire extending longitudinally through the fibre spaced apart from the fibre axis; wherein, in use, electrical power applied to the resistance wire causes the temperature of the resistance wire to increase.
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Gribkoff, Valentin K.
Alavian, Kambiz N.
Tierney, Travis S.
Abrégé
The invention is directed to a method for identifying a candidate anti-glioma drug that is a mitochondrial F1Fo ATP Synthase c-subunit leak channel opener, the method comprising: a. providing an admixture comprising: i. a candidate drug; ii. a submitochondrial vesicle (SMV) preparation; and iii. an H+ probe, wherein the H+ probe remains outside of the SMV(s); b. contacting the admixture with ATP; c. measuring a level of H+ outside of the SMV(s) via the H+ probe; d. comparing the level of H+ at step c) with a level of H+ in a control admixture lacking the candidate drug; and identifying the drug as a candidate anti-glioma drug that is a mitochondrial F1Fo ATP Synthase c-subunit leak channel opener, when the level of H+ is higher compared to the level of H+ in the control admixture; or identifying that the drug is not a candidate anti-glioma drug that is a mitochondrial F1Fo ATP Synthase c-subunit leak channel opener, when the level of H+ is the same or lower compared to the level of H+ in the control admixture.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Rodriguez Manzano, Jesus
Moniri, Ahmad
Miglietta, Luca
Georgiou, Pantelis
Abrégé
Disclosed herein are methods and systems for determining optimal primer sets for a multiplex assay, each of the optimal primer sets intended to amplify one or more targets. The method comprises obtaining amplification data from a plurality of preparatory assays. The amplification data describes at least the amplification of a first target of the one or more targets by a first primer set in a first preparatory assay, the amplification of the first target amplified by a second primer set in a second preparatory assay, the amplification of a second target of the one or more targets by the first primer set in a third preparatory assay, and the amplification of the second target by the second primer set in a fourth preparatory assay. The method further comprises determining a plurality of similarity metrics, each similarity metric being indicative of a degree of similarity between the amplification data produced by one of the plurality of preparatory assays compared to another one of the preparatory assays. The method further comprises determining, based on the plurality of similarity metrics, the optimal primer sets for the multiplex assay.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Rintoul, Jean
Grossman, Nir
Abrégé
The present disclosure relates to a method and system for measuring electric field at a location in a volume of an electrolytic medium and a method and system for applying an electric field to a location in a volume of an electrolytic medium. An aspect of the disclosure provides a method of determining an electric field at a location in a volume of an electrolytic medium, the method comprising: applying, to the location, acoustic energy having a first frequency; sensing an electric field for the volume to obtain a sensed electric field signal; determining, based on the sensed electric field signal and based on a reference signal having the first frequency, the electric field at the location, the electric field at the location having a second frequency.
A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio
A61B 5/24 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61N 1/40 - Application de champs électriques par couplage inductif ou capacitif
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Moore, James
Abrégé
An injection device comprising: a first barrel for containing a first fluid, and having a first plunger; a second barrel for containing a second fluid, and having a second plunger, the second barrel being arranged to one side of the first barrel; a flow converging chamber in fluid communication with the second barrel, for receiving, in use, a flow of the second fluid from the second barrel when the second plunger is advanced within the second barrel; a first inlet to the flow converging chamber, in communication with the first barrel, for receiving, in use, a flow of the first fluid from the first barrel when the first plunger is advanced within the first barrel, simultaneously with the advancement of the second plunger, and arranged to introduce the flow of the first fluid in a concentric manner within the flow of the second fluid, at a meeting point within the flow converging chamber, to produce a concentric flow of the first fluid within the second fluid; and an outlet of the flow converging chamber, for outwardly delivering the concentric flow of the first fluid within the second fluid. The first fluid may contain biological materials such as cells, and may for example comprise a hydrogel. The second fluid may comprise an aqueous fluid such as phosphate-buffered saline. Also provided is a method of delivering a concentric flow of a first fluid within a second fluid, using such an injection device.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Au, Sam H.
Ashby, Julian F.
Abrégé
The present disclosure relates to a microfluidic device for discriminating between second cells, as a function of binding strength between first cells and the second cells, the device comprising: a microfluidic channel, a base of the channel comprising a substrate; wherein the channel is configured to receive first cells, for adhesion of the first cells to the substrate; receive second cells, for adhesion of the second cells to the first cells; and receive a fluid, for fluid flow over the second cells; and wherein a transverse cross-section of the channel is configured for application of a substantially uniform shear stress to the second cells that are adhered to the first cells in at least a central region of the channel as the fluid flows along the channel, to detach at least some of the second cells from the first cells, and to cause the detached second cells to flow towards a downstream end of the channel.
The present invention relates to the use of ultrasound imaging techniques and computer implemented image processing methods for determining and assessing male infertility, as well as non-invasive diagnostic methods to identify and diagnose male infertility, such as hypogonadism (testosterone deficiency). Furthermore, the invention relates to methods of selecting male subjects for fertility treatment and methods for the treatment of these subjects. There is described a computer-implemented method for assessing testicular function in a male subject, the method comprising: receiving one or more ultrasound image collected using contrast-enhanced ultrasound (CEUS) and/or super-resolution ultrasound (SRUS); determining one or more testicular parameters from the one or more ultrasound images; comparing the one or more parameters to one or more threshold values of the one or more parameters; determining a difference between the one or more parameters and the one or more threshold values; and outputting an indication of testicular function based on the comparison of the one or more parameters with the one or more threshold values.
G03B 42/00 - Production d'enregistrements en utilisant d'autres ondes que des ondes optiquesVisualisation de ces enregistrements en utilisant des moyens optiques
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Salerno, Benji Fenech
Holicky, Martin
Torrisi, Felice
Abrégé
The present disclosure is related to processes for the manufacture of electrolyte-gated graphene field effect transistors comprising deposition of ink compositions comprising graphene to form conductive films comprising graphene and the use of said transistors as chemo- and bio-sensors.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Hajitou, Amin
Suwan, Keittisak
Abrégé
The invention relates to phage vectors, and to novel phage vectors comprising transgenes, in particular conventional mammalian transgene cassettes. The invention extends to the use of such phage vectors as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Xu, Xiao-Ning
Lou, Hantao
Guo, Jia
Abrégé
An antibody or antigen-binding fragment thereof is described which binds to the spike protein S2 domain of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome-related coronavirus (MERS-CoV) and/or severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). The antibodies can be used in the diagnosis and treatment of coronavirus infection. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions, diagnostic compositions, and kits. The invention also extends to methods of making and using the antibodies, for example in the diagnosis and therapy of coronavirus infections.
A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Godbold, Ollie
Walker, Max
Price, Matt
Frenette, Leah
Broto-Aviles, Marta
Stevens, Molly
Abrégé
An apparatus for a diagnostic testing device, the diagnostic testing device comprising a plunger for delivering a fluid for use in a diagnostic test, the apparatus comprising: a wire-based muscle-like actuator; circuitry configured to heat, and cause a corresponding contraction of, the wire-based muscle-like actuator; and a lever mechanically coupled to the wire-based muscle-like actuator such that contraction of the wire-based muscle-like actuator actuates the lever from a first position to a second position for activating the plunger to deliver the fluid.
G05D 23/02 - Commande de la température sans source d'énergie auxiliaire avec un élément sensible se dilatant et se contractant en réponse aux variations de température
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Xu, Xiaoning
Ma, Weiwei
Qian, Yuxin
Abrégé
The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating, and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention is also concerned with methods for expansion of MAIT cells in vitro.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Xu, Xiaoning
Ma, Weiwei
Abrégé
The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to anti-T-cell receptor (TCR) V-beta CARs, and to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention extends to genetic constructs per se, and to their use in generating the CAR-MAIT cells, and to transduced CAR-MAIT cells per se. The invention also extends to various medical uses of the constructs and transduced CAR-MAIT cells, and to pharmaceutical compositions comprising these constructs and CAR-MAIT cells.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
68.
GENETIC CONSTRUCTS FOR LOCALISED POPULATION SUPPRESSION
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Burt, Austin
Willis, Katie
Abrégé
The invention relates to genetic constructs, and in particular to genetic constructs for use in population suppression, and pest control. The invention particularly relates to genetic constructs capable of disrupting a haplo-sufficient gene needed for survival or reproduction in an organism, wherein the genetic construct encodes a genomic editor that creates a dominant lethal or sterile mutation in a target gene of the organism. The invention is also concerned with methods of suppressing wild-type populations by use of the genetic constructs described herein.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Schneider, Michael
Newton, Gary
Chapman, Katie
Perrior, Trevor
Jarvis, Ashley
Low, Caroline
Aqil, Rehan
Fisher, Martin
Bayford, Melanie
Chapman, Nicholas
Martin, Nicholas
Reisinger, Tifelle
Negoita-Giras, Gabriel
Fiedler, Lorna R.
Abrégé
This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I).
This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I).
C07F 9/6561 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Hickmott, Jack
Alton, Eric
Griesenbach, Uta
Prasertsuk, Possawee
Abrégé
The present invention relates to nucleic acid cassettes for gene therapy, particularly to nucleic acid cassettes encoding therapeutic proteins in combination with exogenous signal peptides. The invention further relates to viral and non-viral vectors comprising such nucleic acid cassettes, and the use of such nucleic acid cassettes and vectors to increase expression of therapeutic proteins by airway cells.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/535 - CSF du type granulocyteCSF du type granulocyte-macrophage
C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Domoney, Claire
Rayner, Tracey Jane
Frost, Gary
Wilde, Pete
Petropoulou, Aikaterini
Edwards, Cathrina Hansen
Abrégé
The invention relates to methods for determining if a pea variety or a product derived from that pea variety has improved digestion properties. The invention also relates to methods of improving the digestion property of a pea, as well as method of making such plants.
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p. ex. de fibres diététiques
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Karolcik, Stefan
Georgiou, Pantelis
Abrégé
Disclosed herein is a photoplethysmography (PPG) system for health monitoring. The system comprises a first sensor array configured to collect first PPG data and configured for attachment to a patient at a first sensing site; a second senor array configured to collect second PPG data and configured for attachment to the patient at a second sensing site; and one or more processors configured to receive the first and second PPG data and determine, based on the first and second PPG data and a known distance between the first and second sensing site, a blood pressure value for the patient.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Xu, Xiaoning
Ma, Weiwei
Zhao, Lan
Abrégé
The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to anti-CD4 CARs, and to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention extends to genetic constructs per se, and to their use in generating the CAR-MAIT cells, and to transduced CAR-MAIT cells per se. The invention also extends to various medical uses of the constructs and transduced CAR-MAIT cells, and to pharmaceutical compositions comprising these constructs and CAR-MAIT cells.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Fuchter, Matthew J
Brady, Hugh Jm
Huarte, Amaia Uriz
Abrégé
This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of NK cells by increasing the expression of specific transcription factors associated with NK cell production using a new library of compounds.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Mcdonald, Julie
Yip, Alexander
King, Olivia
Abrégé
The present invention relates to antibiotic-resistant bacteria, and to the prevention or treatment of infections of drug-resistant pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE) and/or vancomycin-resistant Enterococcus (VRE). In particular, the invention relates to the treatment or prevention of colonisation of CRE and/or VRE in the gastrointestinal (GI) tract, before they cause invasive infections, for example in the blood. The invention provides novel formulations, pharmaceutical compositions and methods of using them to prevent or treat CRE and/or VRE infections or intestinal colonisations thereof.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST (Royaume‑Uni)
Inventeur(s)
Ng, Fu Siong
Sau, Arunashis
Wright, Ian
Ahmed, Amar
Abrégé
An implantable stimulation device is described. The device comprises: signal receiving means for receiving a signal from a heart; and signal delivery means for delivering an output signal to the heart. In response to receiving the signal from the signal receiving means, the implantable stimulation device configured to determine whether the signal is indicative of ventricular tachycardia. Upon positive determination that the signal is indicative of ventricular tachycardia, determine whether the signal is indicative of sustained ventricular tachycardia or spontaneously-terminating ventricular tachycardia. Upon positive determination that the signal is indicative of sustained ventricular tachycardia, send an output signal via the signal delivery means, else if upon positive determination that the signal is indicative of spontaneously-terminating ventricular tachycardia, delay sending the output signal via the signal delivery means.
An attachment for use with a device to scan a surface, for example a bony surface, the attachment comprising: a first housing portion configured to releasably secure a device comprising a camera, a second housing portion connected to the first housing portion and having a wall defining an internal region of the second housing portion and an external region of the second housing portion, and a plurality of pins slidably secured to the wall, each of the plurality of pins having a proximal end disposed in the internal region and a distal end disposed in the external region. Upon abutment of the distal end of each of the pins against a surface, the proximal end of each of the pins is configured to translate relative to the wall. When the device is secured to the first housing portion, the proximal ends of the plurality of pins are viewable by the camera.
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
H04M 1/04 - Supports pour microphones ou écouteurs
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
UNIVERSITY OF SHEFFIELD (Royaume‑Uni)
ROYAL PAPWORTH HOSPITAL NHS FOUNDATION TRUST (Royaume‑Uni)
Inventeur(s)
Wilkins, Martin
Rhodes, Christopher James
Lawrie, Allan
Errington, Niamh
Wang, Dennis
Toshner, Mark
Abrégé
There is provided methods for diagnosing or aiding diagnosis of pulmonary hypertension (PH), pulmonary arterial hypertension (PAH), and/or chronic thromboembolic pulmonary hypertension (CTEPH) in a subject, determining a subject's risk of developing PH, PAH and/or CTEPH, and/or determining a suitable course of treatment for a subject with PH, PAH and/or CTEPH. The present invention also provides kits comprising means for detecting expression of a panel of microRNAs in a sample.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Abouelela, Aida Rafat
Hallett, Jason Patrick
Firth, Anton Edward Josef
Levers, Oliver Douglas
Abrégé
A method for recycling dye from a dyed textile, the method comprising providing a textile coloured with a dye; adding the textile to a bath comprising a solution of ionic liquid, thereby causing the dye to strip from the textile and to disperse within said solution.
D06P 5/13 - Coloration fugitive ou démontage des colorants
D06P 1/00 - Procédés généraux de teinture ou d'impression des textiles ou procédés généraux de teinture du cuir, des fourrures ou des substances macromoléculaires solides de toutes formes, classés selon les teintures, les pigments ou les substances auxiliaires utilisés
D06P 1/66 - Composés contenant des groupes ammonium contenant des groupes ammonium quaternaire
D06P 1/92 - Procédés généraux de teinture ou d'impression des textiles ou procédés généraux de teinture du cuir, des fourrures ou des substances macromoléculaires solides de toutes formes, classés selon les teintures, les pigments ou les substances auxiliaires utilisés utilisant des colorants dissous dans des solvants organiques ou leurs émulsions aqueuses dans des solvants organiques
D06P 5/20 - Traitements physiques influant sur la coloration, p. ex. ultrasons ou électricité
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Torrisi, Felice
Li, Sihui
Wittmann, Francesca
Abrégé
Described herein are processes for preparation of flexible fibres coated in 2-dimensional materials. These fibres are suitable for use in electronic devices and may be woven to form electronic textiles.
D06M 11/30 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec des halogènesTraitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec des hydracides halogénés ou leurs selsTraitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec des oxydes ou des oxyacides d'halogènes ou leurs sels avec des oxydes d'halogènes, des oxyacides d'halogènes ou leurs sels, p. ex. avec des perchlorates
D06M 11/52 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec du soufre, du sélénium, du tellure, du polonium ou leurs composés avec du sélénium, du tellure, du polonium ou leurs composésTraitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec du soufre, du sélénium, du tellure, du polonium ou leurs composés avec du soufre, des dithionites ou des composés contenant du soufre et des halogènes, avec ou sans oxygèneTraitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec du soufre, du sélénium, du tellure, du polonium ou leurs composés par sulfohalogénation avec l'acide chlorosulfoniqueTraitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec du soufre, du sélénium, du tellure, du polonium ou leurs composés par sulfohalogénation avec un mélange de dioxyde de soufre et d'halogènes libres
D06M 11/58 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec de l'azote ou ses composés, p. ex. avec des nitrures
D06M 11/74 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec du carbone ou ses composés avec du carbone ou du graphiteTraitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec du carbone ou ses composés avec des carburesTraitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec du carbone ou ses composés avec des acides graphitiques ou leurs sels
H01M 4/133 - Électrodes à base de matériau carboné, p. ex. composés d'intercalation du graphite ou CFx
H01M 4/1393 - Procédés de fabrication d’électrodes à base de matériau carboné, p. ex. composés au graphite d'intercalation ou CFx
H01M 4/587 - Matériau carboné, p. ex. composés au graphite d'intercalation ou CFx pour insérer ou intercaler des métaux légers
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Shattock, Robin
Mckay, Paul
Watson, Michael
Harper, Elaine
Abrégé
The present invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Cavuto, Matthew L.
Pennisi, Ivana
Rodriguez Manzano, Jesus
Georgiou, Pantelis
Abrégé
A lid assembly for a sample tube, for collecting magnetic beads from the sample tube and subsequently releasing said beads, the lid assembly comprising: a closure part including means for removably attaching the closure part to the opening of the sample tube, to close the sample tube, and a bead-collecting platform arranged to locate within or above the opening of the sample tube when the closure part is attached to the sample tube, wherein the bead-collecting platform has a bead-collecting surface on one side, for coming into contact with liquid in the sample tube during use, and a magnet-receiving cavity on the other side, behind the bead-collecting surface; and a magnet-bearing part comprising a magnet, wherein the magnet is removably insertable into the magnet-receiving cavity, towards the bead-collecting surface, such that, when the magnet is present within the magnet-receiving cavity, the magnet is capable of holding magnetic beads against the bead-collecting surface, and when the magnet is not present within the magnet-receiving cavity, the lid assembly is incapable of magnetically holding magnetic beads against the bead-collecting surface. Also provided is a method of using such apparatus to collect magnetic beads from a liquid within a sample tube, and associated kits and accessories.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Gartside, Jack
Stenning, Kilian
Vanstone, Alex
Holder, Holly
Branford, William
Oulton, Rupert
Abrégé
A device (1) for use as a physical neural network is described. The device includes a plurality of artificial neurons (2). Each artificial neuron includes a ferromagnetic thin-film nanomagnetic structure (3) having a respective switchable magnetic state. The device is responsive to input data taking the form of a field generated by a control apparatus (5). The input data is for switching one or more of the magnetic states and/or for exerting control over spin-wave dynamics of one or more of the magnetic states. The magnetic states and/or the spin-wave dynamics are readable by one or more sensors (6) to provide output data.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Griesenbach, Uta
Alton, Eric
Juarez-Molina, Claudia Ivette
Lund-Palau, Helena
Bell, Robyn
Morgan, Cliff
Shattock, Robin
Abrégé
The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors which drive transient and/or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), which provide a therapeutic effect without therapy-associated toxicity. The invention further relates to related products and an animal model of aPAP.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Ye, Yu
Morten, Michael
Abrégé
The invention relates to methods of screening for the presence of proteopathies, to methods of diagnosing proteopathies, to methods of differentially diagnosing proteopathies, to methods of assessing the severity, stage and/or prognosis of proteopathies, and to methods for monitoring the progression of proteopathies. The invention also relates to methods for determining the efficacy of therapeutic interventions for proteopathies.
G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Murray, Robert
Battle, Ronan
Abrégé
Laser systems are provided. The laser systems comprise a pump laser source configured to generate pump laser pulses; a first nonlinear medium; and a second nonlinear medium. A cascade of nonlinear processes leads to the generation of optical pulses at different wavelengths. Methods of generating optical pulses are also provided.
H01S 3/00 - Lasers, c.-à-d. dispositifs utilisant l'émission stimulée de rayonnement électromagnétique dans la gamme de l’infrarouge, du visible ou de l’ultraviolet
H01S 3/23 - Agencement de plusieurs lasers non prévu dans les groupes , p. ex. agencement en série de deux milieux actifs séparés
89.
Processing an Arterial Doppler Ultrasound Waveform
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Normahani, Pasha
Jaffer, Usman
Abrégé
A computer-implemented method is disclosed. The method comprises classifying an arterial Doppler ultrasound waveform using the arterial Doppler ultrasound waveform and/or a set of features extracted from the arterial Doppler ultrasound waveform using one or more trained machine learning models to identify whether a peripheral arterial disease condition is present and/or to predict a medical outcome related to peripheral arterial disease. The method comprises, upon identifying the presence of the peripheral arterial disease condition and/or predicting the medical outcome, signalling the presence of the peripheral arterial disease condition and/or the medical outcome.
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Shattock, Robin
Stevens, Molly
Zhu, Yunqing
Blakney, Anna
Abrégé
The invention relates to polymeric compositions, nanoparticles and vaccines comprising polymeric compositions. The invention extends to medical uses of the polymeric compositions, nanoparticles and vaccines. The invention further extends to methods of producing the polymeric compositions and nanoparticles.
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Hajitou, Amin
Suwan, Keittisak
Albahrani, Mariam
Waramit, Sajee
Abrégé
The present invention provides phagemid vectors and associated phagemid particles for cancer treatment, and in particular, to the use of novel phagemid particles and associated expression systems for the treatment, prevention, amelioration, or management of cancer. In particular, the invention relates to the use of phagemid particles and expression systems for the delivery of transgenes encoding cytokines, for the treatment, prevention, amelioration, or management of cancer. The invention also extends to the use of phagemid particles and expression systems for the delivery of transgenes, and for the combination of such treatment with the use of adoptively transferred T cells, for the treatment, prevention, amelioration, or management of cancer.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Hickmott, Jack
Griesenbach, Uta
Alton, Eric
Abrégé
The present invention relates to retroviral vectors modified to improve transgene expression. In particular, the invention relates to retroviral vectors lacking an endogenous Rev response element (RRE) and comprising an intron, particularly a chimeric intron, into which an RRE has been inserted, as well as methods of production and uses thereof.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Hubbell, Jeffrey A.
Randi, Anna M.
Ishihara, Jun
Ishihara, Ako
Briquez, Priscilla
Starke, Richard
Abrégé
The methods and compositions described herein address the need in the art by providing peptides and polypeptides comprising a growth factor binding domain. In some embodiments, the peptides have an amino acid sequence that is at least 80% identical to one of SEQ ID NOS:1-7, 13-15, 49-50, or 66-70, or a fragment thereof; wherein the peptide is less than 300 amino acids in length.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
C07K 14/475 - Facteurs de croissanceRégulateurs de croissance
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Hodes, Marc
Dinh, Hy
Bahadur, Vaibhav
Crowdy, Darren, G.
Mayer, Michael
Kirk, Toby
Abrégé
The present disclosure describes a system and method involving a mechanism for a microfluidic pump that leverages alternating adverse and favorable thermocapillary stresses along menisici in a periodically fully-developed internal flow in a microchannel. The system includes interdigitated hot and cold ridges that are asymmetrically disposed relative to each other. The asymmetrical configuration results in different widths of the menisci which drives the microfluidic pump based on the favorable and adverse thermocapillary stresses.
F28D 15/02 - Appareils échangeurs de chaleur dans lesquels l'agent intermédiaire de transfert de chaleur en tubes fermés passe dans ou à travers les parois des canalisations dans lesquels l'agent se condense et s'évapore, p. ex. tubes caloporteurs
F28F 13/16 - Dispositions pour modifier le transfert de chaleur, p. ex. accroissement, diminution en appliquant un champ électrostatique au noyau des sources de potentiel calorifique
F28F 13/02 - Dispositions pour modifier le transfert de chaleur, p. ex. accroissement, diminution en influençant la couche limite
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
NK:IO LTD (Royaume‑Uni)
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (Royaume‑Uni)
Inventeur(s)
Brady, Hugh J. M.
Fuchter, Matthew
Ang, Heather
Burr, Joanna
Gestwa, Michelle
Koksal, Nahide
Abrégé
This invention relates to expanded Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to increasing the number of CD16+ NK cells within expanded NK cell populations without the need for exogenous gene expression.
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Karadimitris, Anastasios
Rowan, Aileen
Abrégé
The invention relates to chimeric antigen receptors (CARs) per se, to CAR constructs, and to T-cell receptor (TCR) beta-chain variable region beta (TCRVβ) CARs. The invention relates to the use of the CARs in immunotherapy, for example in treating, preventing or ameliorating cancer, such as T-cell malignancies, and also conditions caused or implicated by pathogenic T cells, such as autoimmune diseases. The invention is especially concerned with conventional T cells and invariant natural killer T (iNKT) cells expressing anti-TCRVβ CARs and methods for making the same. The invention extends to nucleic acids and vectors encoding the anti-TCRVβ CARs, and to pharmaceutical compositions comprising the constructs and cells, and to medical uses of the compositions, anti-TCRVβ CAR constructs and T cells and iNKT cells expressing anti-TCRVβ CARs.
Imperial College Innovations Limited (Royaume‑Uni)
Inventeur(s)
Muir, Martin
Hewson, Robert W.
Santer, Matthew
Nightingale, Morgan D.
Abrégé
An aircraft arrangement is provided, the aircraft arrangement including a first aircraft component for converting at least one input vibration into an output vibration suitable for driving an energy harvester, and an energy harvester coupled to the first aircraft component and configured to generate electrical energy in response to the output vibration of the first aircraft component, the first aircraft component including a three-dimensional lattice structure including a multiplicity of unit cells, the unit cells including multiple lattice-forming members, the unit cells having a mean greatest dimension of at least 10 nm.
H02N 2/18 - Machines électriques en général utilisant l'effet piézo-électrique, l'électrostriction ou la magnétostriction fournissant une sortie électrique à partir d'une entrée mécanique, p. ex. générateurs
B64D 41/00 - Installations génératrices de puissance pour servitudes auxiliaires
100.
METHOD AND APPARATUS FOR REDUCING THE NOISE TEMPERATURE OF SYSTEMS COMPRISING SAMPLES WHICH INTERACT WITH OSCILLATING ELECTROMAGNETIC FIELDS SUPPORTED BY ELECTROMAGNETIC RESONATORS
IMPERIAL COLLEGE INNOVATIONS LIMITED (Royaume‑Uni)
Inventeur(s)
Kuan-Cheng, Chen
Oxborrow, Mark
Abrégé
An aspect of the disclosure provides an apparatus comprising: an electromagnetic resonator configured to support an oscillating electromagnetic field in a sample; a cold load having a noise temperature lower than the noise temperature of the electromagnetic resonator; a coupler controllable to provide: a first coupling between the electromagnetic resonator and the cold load to reduce the noise temperature of the electromagnetic resonator; a second coupling, different from the first coupling, to the electromagnetic resonator for sensing an electromagnetic field associated with the sample.